

# Focus On Capillaroscopic Ulcer index in Systemic sclerosis

<b>Submission date</b> 10/02/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 18/03/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 14/08/2019	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Oliver Distler

**Contact details**  
University Hospital Zürich  
Gloriastrasse 25  
Zürich  
Switzerland  
8091

## Additional identifiers

## Study information

**Scientific Title**  
Focus On Capillaroscopic Ulcer index in Systemic sclerosis: a national, multi-centre, prospective, observational, non-interventional pilot study

**Acronym**  
FOCUS

**Study objectives**

To describe the change of the capillaroscopic skin ulcer risk index during the natural course of the disease and with bosentan treatment (in patients newly needing bosentan treatment by the decision of the physician).

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Cantonal Ethics Committee Zürich, approved on 15.10.2010, KEK-ZH-Nr. 2010-0301/5

### **Study design**

Multicentre prospective observational non-interventional pilot study

### **Primary study design**

Observational

### **Study type(s)**

Screening

### **Health condition(s) or problem(s) studied**

Systemic sclerosis

### **Interventions**

Capillaroscopic values (amount of capillaries, amount of megacapillaries and diameter of megacapillaries) are being documented over a one year period

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome(s)**

Change of the capillaroscopic skin ulcer risk index (CSURI) over time with or without specific treatment

Outcomes are measured at one year

### **Key secondary outcome(s)**

1. Change of other capillaroscopic images, number of DU, appearance of new DU, change of Raynaud Condition Score, modified Rodnan skin score, amount of DU complications over time with or without specific treatment
2. Correlation of the CSURI with number of DUs, Raynaud condition score and other vascular complications
3. Comparison local versus central analysis of CSURI

Outcomes are measured at one year

### **Completion date**

20/02/2013

# Eligibility

## Key inclusion criteria

1. Definitive diagnosis of systemic sclerosis (SSc) by the American College of Rheumatology (ACR) criteria
2. History of documented digital ischaemic ulcers secondary to SSc within the past year prior to enrolment or with at least one active digital ischaemic ulcer (DU) at enrolment
3. Signed patient informed consent form

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Sex

All

## Total final enrolment

61

## Key exclusion criteria

1. Patient refused to sign the patient informed consent
2. DUs due to a condition other than SSc
3. DU associated with calcinosis
4. Treatment with parenteral prostanoids or Tracleer®) within the past 3 months before enrolment
5. Treatment with phosphodiesterase-5-inhibitors (PDE-5-I), except for intermittent treatment of male erectile dysfunction
6. Treatment with other Endothelin-receptor-antagonists (ERA)
7. Patients receiving any other experimental treatment
8. Patients receiving systemic antibiotics for infected ulcers
9. Patients with active renal crisis or advanced cardiopulmonary disease or who are otherwise clinically unstable

## Date of first enrolment

20/02/2011

## Date of final enrolment

20/02/2013

# Locations

## Countries of recruitment

Switzerland

**Study participating centre**  
**University Hospital Zürich**  
Zürich  
Switzerland  
8091

## Sponsor information

**Organisation**  
Actelion Pharma Schweiz AG (Switzerland)

**ROR**  
<https://ror.org/001yedb91>

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Actelion Pharmaceuticals

**Alternative Name(s)**  
Actelion Pharmaceuticals Ltd

**Funding Body Type**  
Private sector organisation

**Funding Body Subtype**  
For-profit companies (industry)

**Location**  
Switzerland

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	25/10/2018	14/08/2019	Yes	No